Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan

Background/Objective: The incidence of psoriasis vulgaris in Asians is estimated at 0.05–0.30%. Studies in North America and Europe demonstrated that adalimumab, a fully human monoclonal IgG1 antibody, is an efficacious treatment for psoriatic arthritis and chronic plaque psoriasis. The aim of this...

Full description

Bibliographic Details

Published in:	Dermatologica Sinica
Main Authors:	Pei-Han Kao, Rosaline Chung-Yee Hui, Chih-Hsun Yang, Yu-Huei Huang
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-09-01
Subjects:	adalimumab psoriasis arthritis tumor necrosis factor antagonist
Online Access:	http://www.sciencedirect.com/science/article/pii/S1027811714000615